Davenport & Co’s Intellia Therapeutics NTLA Stock Holding History

Davenport & Co’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,800	Closed	-$1.26M	–	1039
2021 Q2	$1.26M	Sell	7,800 -5,200	-40%	-$405K	0.01%	429
2021 Q1	$1.04M	Sell	13,000 -5,000	-28%	-$336K	0.01%	386
2020 Q4	$979K	Sell	18,000 -1,200	-6%	-$43.6K	0.01%	378
2020 Q3	$382K	Buy	+19,200	New	+$400K	﹤0.01%	523

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Davenport & Co's NTLA Position: Q3 2021 in Review

Davenport & Co sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 7,800 shares — an estimated $1.26M sold.

Davenport & Co first reported a position in NTLA in Q3 2020 and held it in 4 quarters. The position peaked at $1.26M in Q2 2021. 364 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

Davenport & Co reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
Davenport & Co sold 7,800 Intellia Therapeutics shares in Q3 2021, an estimated $1.26M.
Davenport & Co first reported a position in Intellia Therapeutics in Q3 2020 and held it in 4 quarters.
Davenport & Co's Intellia Therapeutics position peaked at $1.26M in Q2 2021.
364 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Davenport & Co's 13F filing for Q3 2021, filed 14 Oct 2021.